Abstract
Purpose
This study aims to expand our understanding of the mechanisms of drug absorption, distribution, metabolism and excretion in the Göttingen minipig to aid a knowledge-driven selection of the optimal species for preclinical pharmaceutical research.
Methods
The pharmacokinetics of seven reference compounds (antipyrine, atenolol, cimetidine, diazepam, hydrochlorothiazide, midazolam and theophylline) was investigated after intravenous and oral dosing in minipigs. Supportive in vitro data were generated on hepatocellularity, metabolic clearance in hepatocytes, blood cell and plasma protein binding and metabolism routes.
Results
Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine). Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide. A gender-related difference of in vivo metabolic clearance was observed for antipyrine. The hepatocellularity for minipig was determined as 124 Mcells/g liver, similar to the values reported for human. Based on these data a preliminary in vitro to in vivo correlation (IVIVC) for metabolic clearance measured in hepatocytes was investigated. Metabolite profiles of diazepam and midazolam compared well between minipig and human.
Conclusions
The results of the present study support the use of in vitro metabolism data for the evaluation of minipig in preclinical research and safety testing.
Similar content being viewed by others
Abbreviations
- ADME:
-
Absorption, distribution, metabolism and excretion
- AUC:
-
Area under the curve
- CYP:
-
Cytochrome P450
- FCS:
-
Fetal calf serum
- GFR:
-
Glomerular filtration rate
- IVIVC:
-
In vitro-in vivo correlation
- NCA:
-
Non-compartmental analysis
- PBPK:
-
Physiologically-based pharmacokinetic
- PK:
-
Pharmacokinetic
References
Chapman KL, Holzgrefe H, Black LE, Brown M, Chellman G, Copeman C, et al. Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation. Regulat ToxicoL Pharmacol : RTP. 2013;66(1):88–103.
Zbinden G. The concept of multispecies testing in industrial toxicology. Regulat ToxicoL Pharmacol : RTP. 1993;17(1):85–94.
Forster R, Bode G, Ellegaard L, van der Laan J-W. The RETHINK project on minipigs in the toxicity testing of new medicines and chemicals: conclusions and recommendations. J Pharmacol Toxicol Methods. 2010;62(3):236–42.
Gutierrez K, Dicks N, Glanzner WG, Agellon LB, Bordignon V. Efficacy of the porcine species in biomedical research. Front Genet. 2015;6.
Simianer H, Kohn F. Genetic management of the Gottingen Minipig population. J Pharmacol Toxicol Methods. 2010;62(3):221–6.
Swindle MM, Makin A, Herron AJ, Clubb Jr FJ, Frazier KS. Swine as models in biomedical research and toxicology testing. Vet Pathol. 2012;49(2):344–56.
Sjogren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, et al. In vivo methods for drug absorption—comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Europ J Pharmaceut Sci : Off J Europ Fed Pharmaceut Sci. 2014;57:99–151.
Suenderhauf C, Parrott N. A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation. Pharm Res. 2013;30:1–15.
Suenderhauf C, Tuffin G, Lorentsen H, Grimm HP, Flament C, Parrott N. Pharmacokinetics of paracetamol in Gottingen Minipigs: in vivo studies and modeling to elucidate physiological determinants of absorption. Pharm Res. 2014.
Christiansen ML, Mullertz A, Garmer M, Kristensen J, Jacobsen J, Abrahamsson B, et al. Evaluation of the use of Gottingen minipigs to predict food effects on the oral absorption of drugs in humans. J Pharm Sci. 2015;104(1):135–43.
Holzgrefe H, Ferber G, Champeroux P, Gill M, Honda M, Greiter-Wilke A, et al. Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium. J Pharmacol Toxicol Methods. 2014;69(1):61–101.
Markert M, Stubhan M, Mayer K, Trautmann T, Klumpp A, Schuler-Metz A, et al. Validation of the normal, freely moving Gottingen minipig for pharmacological safety testing. J Pharmacol Toxicol Methods. 2009;60(1):79–87.
Forster R, Bode G, Ellegaard L, van der Laan JW. The RETHINK project: minipigs as models for the toxicity testing of new medicines and chemicals: an impact assessment. J Pharmacol Toxicol Methods. 2010;62(3):158–9.
Bode G, Clausing P, Gervais F, Loegsted J, Luft J, Nogues V, et al. The utility of the minipig as an animal model in regulatory toxicology. J Pharmacol Toxicol Methods. 2010;62(3):196–220.
van der Laan JW, Brightwell J, McAnulty P, Ratky J, Stark C. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. J Pharmacol Toxicol Methods. 2010;62(3):184–95.
Mahl JA, Vogel BE, Court M, Kolopp M, Roman D, Nogués V. The minipig in dermatotoxicology: methods and challenges. Exp Toxicol Pathol. 2006;57(5–6):341–5.
Dalgaard L. Comparison of minipig, dog, monkey and human drug metabolism and disposition. J Pharmacol Toxicol Methods. 2014.
Skaanild MT. Porcine cytochrome P450 and metabolism. Curr Pharm Des. 2006;12(11):1421–7.
Puccinelli E, Gervasi PG, Longo V. Xenobiotic metabolizing cytochrome P450 in pig, a promising animal model. Curr Drug Metab. 2011;12(6):507–25.
Helke KL, Swindle MM. Animal models of toxicology testing: the role of pigs. Expert Opin Drug Metab Toxicol. 2013;9(2):127–39.
Vree TB, Beneken Kolmer EW, Peeters A. Comparison of the metabolism of four sulphonamides between humans and pigs. Vet Quarter. 1991;13(4):236–40.
Anzenbacherova E, Anzenbacher P, Svoboda Z, Ulrichova J, Kvetina J, Zoulova J, et al. Minipig as a model for drug metabolism in man: comparison of in vitro and in vivo metabolism of propafenone. Biomed Papers Med Faculty Univ Palacky, Olomouc, Czechoslovakia. 2003;147(2):155–9.
Marini S, Longo V, Mazzaccaro A, Gervasi PG. Xenobiotic-metabolizing enzymes in pig nasal and hepatic tissues. Xenobiotica. 1998;28(10):923–35.
Baggot JD. Pharmacokinetic-pharmacodynamic relationship. Annales de recherches veterinaires. Ann Vet Res. 1990;21 Suppl 1:29s–40s.
Martinez M, Amidon G, Clarke L, Jones WW, Mitra A, Riviere J. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. part II. physiological considerations. Adv Drug Deliv Rev. 2002;54(6):825–50.
Toutain PL, Ferran A, Bousquet-Melou A. Species differences in pharmacokinetics and pharmacodynamics. Handb Exp Pharmacol. 2010;199:19–48.
Van Peer E, Verbueken E, Saad M, Casteleyn C, Van Ginneken C, Van Cruchten S. Ontogeny of CYP3A and P-Glycoprotein in the liver and the small intestine of the göttingen minipig: an immunohistochemical evaluation. Basic Clin Pharmacol Toxicol. 2014;114:387–94.
Van Peer E, De Bock L, Boussery K, Van Bocxlaer J, Casteleyn C, Van Ginneken C, et al. Age-related differences in CYP3A abundance and activity in the liver of the Gottingen minipig. Basic Clin Pharmacol Toxicol. 2015.
Heckel T, Schmucki R, Berrera M, Ringshandl S, Badi L, Steiner G, et al. Functional analysis and transcriptional output of the Gottingen minipig genome. BMC Genomics. 2015;16(1):932.
Koljonen M, Hakala KS, Ahtola-Satila T, Laitinen L, Kostiainen R, Kotiaho T, et al. Evaluation of cocktail approach to standardise Caco-2 permeability experiments. Europ J Pharmaceut Biopharmaceut : Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2006;64(3):379–87.
Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther. 1996;59(6):613–23.
Collett A, Sims E, Walker D, He YL, Ayrton J, Rowland M, et al. Comparison of HT29-18-C1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption. Pharm Res. 1996;13(2):216–21.
Reeves PR, McAinsh J, McIntosh DA, Winrow MJ. Metabolism of atenolol in man. Xenobiotica. 1978;8(5):313–20.
Sitsen JMA, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug–drug interaction study in healthy male subjects. E J Clin Pharmacol. 2000;56(5):389–94.
Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet. 1983;8(6):463–95.
Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;182:335–60.
Beermann B, Groschinsky-Grind M, Rosen A. Absorption, metabolism, and excretion of hydrochlorothiazide. Clin Pharmacol Ther. 1976;19(5 Pt 1):531–7.
Patel RB, Patel UR, Rogge MC, Shah VP, Prasad VK, Selen A, et al. Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci. 1984;73(3):359–61.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.
Thummel KE, O’Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59(5):491–502.
Zhang Z-Y, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995;50(2):205–11.
Lennernas H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr Drug Metab. 2007;8(7):645–57.
Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23.
Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Disposition: Biol Fate Chem. 2008;36:1385–405.
Taylor EA, Turner P. The distribution of propranolol, pindolol and atenolol between human erythrocytes and plasma. Br J Clin Pharmacol. 1981;12(4):543–8.
Paixao P, Gouveia LF, Morais JA. Prediction of drug distribution within blood. Europ J Pharmaceut Sci : Off J Europ Fed Pharmaceut Sci. 2009;36(4–5):544–54.
Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, Teramura T. A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos. 2010;38(2):308–16.
Gertz M, Houston JB, Galetin A. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos. 2011;39(9):1633–42.
Mitenko PA, Ogilvie RI. Pharmacokinetics of intravenous theophylline. Clin Pharmacol Ther. 1973;14(4):509–13.
Downs TR, Wilfinger WW. Fluorometric quantification of DNA in cells and tissue. Anal Biochem. 1983;131(2):538–47.
Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol. 1976;13:29–83.
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76–85.
Carlile DJ, Zomorodi K, Houston JB. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab Dispos. 1997;25(8):903–11.
Cibulskyte D, Kaalund H, Pedersen M, Horlyck A, Marcussen N, Hansen HE, et al. Chronic cyclosporine nephrotoxicity: a pig model. Transplant Proc. 2005;37(8):3298–301.
Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics : concepts and applications. 4th ed. Philadelphia: Wolters Kluwer Health/Lippincott William & Wilkins, c2011; 2005.
Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1973;1(2):123–36.
Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos. 2007;35(3):501–2.
Sohlenius-Sternbeck AK. Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol in vitro : Int J Publ Assoc BIBRA. 2006;20(8):1582–6.
Worboys PD, Bradbury A, Houston JB. Kinetics of drug metabolism in rat liver slices. II. comparison of clearance by liver slices and freshly isolated hepatocytes. Drug Metab Dispos. 1996;24(6):676–81.
Larsson R, Erlanson P, Bodemar G, Walan A, Bertler A, Fransson L, et al. The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. Br J Clin Pharmacol. 1982;13(2):163–70.
Mitchell SC, Idle JR, Smith RL. The metabolism of [14C]cimetidine in man. Xenobiotica. 1982;12(5):283–92.
Dudley AJ, Brown CD. Mediation of cimetidine secretion by P-glycoprotein and a novel H(+)-coupled mechanism in cultured renal epithelial monolayers of LLC-PK1 cells. Br J Pharmacol. 1996;117(6):1139–44.
O’Malley K, Crooks J, Duke E, Stevenson IH. Effect of age and sex on human drug metabolism. Br Med J. 1971;3(5775):607–9.
Teunissen MW, Srivastava AK, Breimer DD. Influence of sex and oral contraceptive steroids on antipyrine metabolite formation. Clin Pharmacol Ther. 1982;32(2):240–6.
Skaanild MT, Friis C. Cytochrome P450 sex differences in minipigs and conventional pigs. Pharmacol Toxicol. 1999;85:174–80.
Chenery R, Ayrton A, Oldham H, Standring P, Norman S, Seddon T, et al. Diazepam metabolism in cultured hepatocytes from rat, rabbit, dog, guinea pig, and man. Drug Metab Dispos. 1987;15(3):312–7.
Hallifax D, Houston JB. Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs. J Pharm Sci. 2012;101(8):2645–52.
Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, Pasanen M. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica. 2007;37(12):1367–77.
Parrott N, Jones H, Paquereau N, Lave T. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin Pharmacol Toxicol. 2005;96(3):193–9.
Jones HM, Parrott N, Jorga K, Lavé T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet. 2006;45:511–42.
Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247–62.
Bouzom F, Ball K, Perdaems N, Walther B. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm Drug Dispos. 2012;33(2):55–71.
ACKNOWLEDGMENTS AND DISCLOSURES
This work was funded by the Roche Post-Doc Fellowship (RPF) Program. We thank all our associates for their support, in particular Anthony Vandjour, Christelle Rapp and Claudia Senn for the in vivo measurements, Hamina Daff, Sandrine Simon, Isabelle Walter, Andreas Goetschi and Pierre - Alexis Gonsard for their work on plasma protein binding and bioanalysis, Aynur Ekiciler for the hepatocellularity evaluation and in vitro intrinsic clearance determination, Peter Schrag for the blood to plasma portioning measurements, Martin Kapps for the LC/MS bioanalysis, and Michaela Marschmann for the investigation of the metabolite profiles.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s11095-016-2026-x.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 244 kb)
Rights and permissions
About this article
Cite this article
Lignet, F., Sherbetjian, E., Kratochwil, N. et al. Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. Pharm Res 33, 2565–2579 (2016). https://doi.org/10.1007/s11095-016-1982-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-016-1982-5